29 completed, 7 unknown, 6 terminated, 3 recruiting. 47 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 47 | Completed 29, Unknown 7, Terminated 6, Recruiting 3, Active not recruiting 2 |
| Phase 2 | 9 | Completed 7, Terminated 1, Unknown 1 |
Follow Hydroxyurea: new trials by email Literature Review of Hydroxyurea trials Research Report on Hydroxyurea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2024-07-16 | 2026-08-27 |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera Givinostat, Hydroxyurea - Polycythemia Vera | Phase 3 | Recruiting | Italfarmaco | 220 | 2024-03-26 | 2026-03-25 |
| Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa Hydroxyurea - Sickle Cell Anemia in Children, Sickle Cell Disease | Phase 3 | Recruiting | Brown University | 400 | 2023-11-15 | 2026-08-20 |
| Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II ) Hydroxyurea - Sickle Cell Anemia in Children | Phase 3 | Completed | Global Health Uganda LTD | 270 | 2021-03-09 | 2025-04-17 |
| Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets - Myelofibrosis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 105 | 2021-02-05 | 2023-11-13 |
| Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients Hydroxyurea and Thalidomide - Thalassemia, Beta | Phase 2 / Phase 3 | Completed | Children's Hospital Karachi | 603 | 2020-07-07 | 2023-12-01 |
| Clinical Experience of Thalidomide in Thalassemic Patients hydroxyurea and thalidomide - Thalassemia, Beta | Phase 2 / Phase 3 | Completed | Children's Hospital Karachi | 135 | 2020-01-01 | 2021-11-24 |
| Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia Omega 3, Nigella Sativa Oil, Hydroxyurea - Iron Overload, Oxidative Stress | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Omega 3, Vit D, Zinc sulfate - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera Ruxolitinib, Hydroxycarbamide, Interferon-Alpha - Polycythemia Vera | Phase 3 | Recruiting | University of Birmingham | 586 | 2019-10-25 | 2026-10-26 |
| Hydroxyurea Optimization Through Precision Study Hydroxyurea - Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Completed | Lifespan | 104 | 2019-01-17 | 2025-06-18 |
| Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients hydroxyurea, Imatinib - Leukemia, Chronic Myeloid | Phase 3 | Unknown | First Affiliated Hospital of Harbin Medical University | 60 | 2018-05-01 | 2018-05-22 |
| Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Thalidomide and Hydroxyurea - Thalassemia | Phase 2 / Phase 3 | Completed | Blood Diseases Clinic | 654 | 2018-01-01 | 2022-03-25 |
| Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas Hydroxyurea - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Completed | Indiana University | 187 | 2017-07-26 | 2020-02-20 |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Pacritinib, Physician's Choice medications - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Active not recruiting | Swedish Orphan Biovitrum | 407 | 2017-06-26 | 2026-04-30 |
| Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa Moderate Dose Hydroxyurea, Low Dose Hydroxyurea - Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Completed | Vanderbilt University Medical Center | 120 | 2017-01-01 | 2022-01-19 |
| Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Realgar-Indigo naturalis formula, all-trans retinoic acid, Arsenic trioxide - Acute Promyelocytic Leukemia | Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 110 | 2016-09-01 | 2021-09-08 |
| Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II Hydroxyurea (Moderate Dose), Hydroxyurea (Low Dose) - Sickle Cell Disease, Stroke | Phase 3 | Completed | Vanderbilt University Medical Center | 440 | 2016-07-19 | 2020-08-03 |
| Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Decitabine, HYDROXYUREA - MDS | Phase 3 | Completed | Groupe Francophone des Myelodysplasies | 170 | 2014-10-14 | 2021-11-19 |
| Novel Use Of Hydroxyurea in an African Region With Malaria Hydroxyurea, Placebo - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Completed | Indiana University | 208 | 2014-09-01 | 2018-12-04 |
Showing 20 of 47. Sign in to see all of them.
Anemia, Sickle Cell (12) · Polycythemia Vera (8) · Leukemia (7) · Leukemia, Myeloid, Chronic-Phase (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Hematologic Diseases (4) · Thrombocythemia, Essential (4) · beta-Thalassemia (4) · Primary Myelofibrosis (3) · Stroke (3) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Malaria (2) · Adenocarcinoma (1) · Anemia (1) · Anemia, Refractory, with Excess of Blasts (1)
AOP Orphan Pharmaceuticals AG (2) · Beni-Suef University (2) · Children's Hospital Karachi (2) · Children's Hospital Medical Center, Cincinnati (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Incyte Corporation (2) · Indiana University (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Vanderbilt University Medical Center (2) · Ain Shams University (1) · Alliance for Clinical Trials in Oncology (1) · Blood Diseases Clinic (1) · Brown University (1) · Consorzio Mario Negri Sud (1) · Eastern Cooperative Oncology Group (1)
United States (14) · France (11) · Germany (10) · Italy (10) · United Kingdom (10) · Spain (8) · Hungary (6) · Poland (6) · China (5) · Austria (4) · Czechia (4) · Russia (4) · Australia (3) · Belgium (3) · Bulgaria (3)
Ruediger Hehlmann, MD (3) · Russell E. Ware, MD, PhD (3) · Ahmed F Mahmoud Hussein, MS.c (2) · Michael R. DeBaun, MD, MPH (2) · Alan K. Burnett, MD, FRCP (1) · Bruce W Thompson, Ph.D. (1) · Chandy C John, M.D. (1) · Chandy C. John, M.D. (1) · Claire Harrison (1) · Claire Harrison, MD (1) · Courtney Thornburg, MD (1) · Dan DeAngelo, MD (1)
PMID 30952488, PMID 15010373, PMID 17315155, PMID 18478575, PMID 19291085, PMID 19621454, PMID 19813252, PMID 19856395, PMID 19880138, PMID 19965667, PMID 20142590, PMID 20797449, PMID 21217080, PMID 21422420, PMID 21571150, PMID 21606305, PMID 21744485, PMID 21826782, PMID 22190441, PMID 22294512, PMID 22318199, PMID 22915643, PMID 23216616, PMID 23315161, PMID 23841729, PMID 23861242, PMID 23927461, PMID 23999955, PMID 24127444, PMID 24162333, PMID 24297946, PMID 24622328, PMID 24658964, PMID 24837466, PMID 24914136, PMID 25465231, PMID 25470713, PMID 25629741, PMID 25918346, PMID 26414435, PMID 26670617, PMID 27102499, PMID 27339303, PMID 27400939, PMID 28193568, PMID 29051184, PMID 29396713, PMID 29479070, PMID 29784451, PMID 30287855
2008 (1), 2009 (1), 2023 (1), N01HB07150 (1), N01HB07151 (1), N01HB07152 (1), N01HB07153 (1), N01HB07154 (1), N01HB07155 (1), N01HB07156 (1), N01HB07157 (1), N01HB07158 (1), N01HB07159 (1), N01HB07160 (1), P01CA108671 (1)